logo-loader
viewChampignon Brands Inc.

Champignon Brands makes ketamine treatment available at major Canadian pharmacy location

The group will also leverage the pharmacy’s infrastructure to distribute ketamine topical prescriptions to a network of medical, pain and addiction clinics in Canada

Champignon Brands Inc. -
A major Canadian pharmacy chain will dispense its ketamine topical treatment at one of its locations

Champignon Brands Inc (CSE:SHRM) (OTCQB:SHRMF) said Thursday that a major Canadian pharmacy chain will dispense its ketamine topical treatment at one of its locations.

The move strengthens Champignon’s vertically integrated psychedelic medicine offering by accelerating its ketamine topicals fulfillment capabilities, the firm said in a statement.

Vancouver-based Champignon will also leverage the pharmacy’s infrastructure to distribute ketamine topical prescriptions to a network of medical, pain and addiction clinics in Canada, broadening the company’s revenue stream.

READ: Champignon Brands inks blockbuster deal to roll out network of psychedelic medicine clinics in North America

The clinics will use Champignon’s formulations to conduct chart reviews and patient studies under human ethics approval from Health Canada and data from the studies will be used to published peer-reviewed mandates and expedite future human clinical trials planned for later this year.

Additionally, Champignon and the pharmacy will design a Level B clean room located at the pharmacy to compound and package the company’s ketamine formulations, which include off-market intranasal esketamine and ketamine topicals. The clean room is anticipated to be completed by 3Q 2020 and will be designed in line with national pharmacy regulatory guidelines.

“With this arrangement, Champignon boasts complete vertical integration with respect to our rapid onset ketamine treatments and therapies,” CEO Gareth Birdsall said in the statement.

“From novel formulations to product development at a purpose-built GMP and DIN licensed pharmaceutical facility, and now automated prescription fulfillment and on-site compounding infrastructure, we have managed to capture the entire product lifecycle,” he added.

Champignon’s central fill capabilities optimizes the company’s prescription fulfilment infrastructure and advance its ketamine data collation initiatives for conditions like concussions and traumatic brain injury, anxiety and treatment-resistant depression.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Champignon Brands Inc.

Price: 0.89 CAD

CSE:SHRM
Market: CSE
Market Cap: $70.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Champignon Brands Inc. named herein, including the promotion by the Company of Champignon Brands Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Champignon Brands charts course for success with acquisitions and a name change

Champignon Brands (CSE: SHRM- OTCQB: SHRMF) CEO Dr Roger McIntyre joined Steve Darling from Proactive Vancouver with news the company is changing its name to Apotheosis, which means the high point of development. McIntyre discusses the thinking behind the change, plus acquisitions and other...

2 weeks, 1 day ago

2 min read